Updated report on incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/1078155218769347
Abstract: Purpose Fosaprepitant (Emend®) is an antiemetic frequently used for the prevention of chemotherapy-induced nausea and vomiting. We previously documented an overall 28.7% incidence of infusion-site reactions in patients receiving fosaprepitant via peripheral venous access. These… read more here.
Keywords: incidence; infusion; infusion site; site reactions ... See more keywords
104-LB: Assessing Infusion Site Reactions with URLi in Continuous Subcutaneous Insulin Infusion
Sign Up to like & getrecommendations! Published in 2021 at "Diabetes"
DOI: 10.2337/db21-104-lb
Abstract: Background: In phase 3 trials, ultra rapid lispro (URLi) showed superior postprandial glucose control and non-inferior HbA1c reduction compared to Humalog® (Lispro). However, infusion site reactions (combined; ISRs) were more frequent with URLi. Methods: We… read more here.
Keywords: infusion; lilly company; infusion site; eli lilly ... See more keywords
Study on the method to avoid infusion-site adverse events following chemotherapeutic treatment with epirubicin and fosaprepitant using immortalized human umbilical vein endothelial cells
Sign Up to like & getrecommendations! Published in 2022 at "Oncology Letters"
DOI: 10.3892/ol.2022.13506
Abstract: The combination of intravenous Proemend® containing fosaprepitant meglumine, a prodrug for fosaprepitant (FAP), and Tween 80 and chemotherapy with anthracyclines, such as epirubicin (EPI), can cause infusion-site adverse events in clinical practice. In immortalized human… read more here.
Keywords: fap epi; infusion site; infusion; site adverse ... See more keywords